DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk During Anti-HCV Treatment

PLoS ONE - United States
doi 10.1371/journal.pone.0167934
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

HCV and Diabetes: Towards a ‘Sustained’ Glycaemic Improvement After Treatment With DAAs?

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2017English

HCV and Diabetes: Towards a ‘Sustained’ Glycaemic Improvement After Treatment With DAAs? – Authors' Reply

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2017English

Rationale for Targeting VEGF, FGF, and PDGF for the Treatment of NSCLC

OncoTargets and Therapy
OncologyPharmacology
2011English

Response Prediction for Chronic HCV Genotype 4 Patients to DAAs

International Journal of Advanced Computer Science and Applications
Computer Science
2016English

The “Real-World” Efficacy and Safety of DAAs for the Treatment of HCV Patients Throughout Japan

Journal of Gastroenterology
Gastroenterology
2018English

Anti-Vegf Treatment Reduces Blood Supply and Increases Tumor Cell Invasion in Glioblastoma

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2011English

Rapidly Changing Seasonal Sea Levels Increase Flood Risk

Eos
EarthPlanetary Sciences
2014English

Estimation of Serum Leptin Level in Egyptian Patients With Chronic HCV After Antiviral Treatment

Journal of Gastroenterology and Hepatology Research
HepatologyGastroenterology
2015English

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Clinical Pharmacokinetics
Pharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy